Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma [0.03%]
新辅助免疫治疗后病理反应和肿瘤病灶的组织病理特征与III期黑色素瘤患者的生存率相关性研究
R V Rawson,C Adhikari,C Bierman et al.
R V Rawson et al.
Background: Guidelines for pathological evaluation of neoadjuvant specimens and pathological response categories have been developed by the International Neoadjuvant Melanoma Consortium (INMC). As part of the Optimal Neo-...
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer [0.03%]
新一代ALK酪氨酸激酶抑制剂lorlatinib治疗ROS1阳性非小细胞肺癌临床研究进展
T E Stinchcombe
T E Stinchcombe
Bayesian interpretation of the ESMO guideline for localized colorectal cancer: a better IDEA [0.03%]
ESMO直肠癌指南的贝叶斯学派解释：比IDEA更好的方法
A Carmona-Bayonas,P Jimenez-Fonseca,V Valenti et al.
A Carmona-Bayonas et al.
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [0.03%]
靶向Trop-2的抗体药物偶联物sacituzumab govitecan治疗实体瘤患者：I/II期IMMU-132-01篮子试验的最终安全性和有效性结果
A Bardia,W A Messersmith,E A Kio et al.
A Bardia et al.
Background: Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter trial (NC...
Multidisciplinary tumor boards present technical and financial challenges in the COVID-19 era [0.03%]
COVID-19大流行下的多学科肿瘤委员会面临的技术和财务挑战
B A Schroeder,E Cuevas,J J Graber
B A Schroeder
Small cell lung cancer: a slightly less orphan disease after immunotherapy [0.03%]
免疫治疗后的略小细胞肺癌：较少被忽视的疾病
J Remon,M Aldea,B Besse et al.
J Remon et al.
Small cell lung cancer (SCLC) is an aggressive malignancy accounting for 15% of all diagnosed cases of lung cancer. After >15 years without any clinically relevant therapeutic advances, extensive-disease SCLC has become the second thoracic ...
Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET inhibitor pralsetinib [0.03%]
新药旧互动—— cilofloxon可增加RET抑制剂Pralsetinib的暴露量
F Citarella,M Russano,A Galletti et al.
F Citarella et al.
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types [0.03%]
高肿瘤突变负荷无法预测所有癌症类型的免疫检查点阻断反应
D J McGrail,P G Pilié,N U Rashid et al.
D J McGrail et al.
Background: High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoanti...
Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428] [0.03%]
撤回《ORIENT-3研究： sintilimab与docetaxel治疗接受过全身治疗的晚期/转移性sqNSCLC患者的III期、开放标签、随机对照研究》一文:[Annals of Oncology 第31卷, Supplement 7期, 2020年12月，第S1428页]
Y Shi,L Wu,X Yu et al.
Y Shi et al.
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article was retracted at the request of the authors. The authors of this abstr...
Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer [0.03%]
MMR缺陷型早期直肠癌患者接受免疫治疗后完全病理性及血清学反应消失
L S Tarpgaard,P V Andersen,N Øgaard et al.
L S Tarpgaard et al.